Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. Co. is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. Co.'s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. We show 45 historical shares outstanding datapoints in our coverage of ATRA's shares outstanding history.
Understanding the changing numbers of ATRA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ATRA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ATRA by allowing them to research ATRA shares outstanding history
as well as any other stock in our coverage universe. |
Free ATRA Email Alerts:
Video: Shares Outstanding Importance
